Infliximab in severe active ankylosing spondylitis with spinal ankylosis

Internal Medicine Journal

Volumn 38, Issue 6 A, 2008, Pages 396-401

  Cheung, P P M ^a,b   Tymms, K E ^a,b   Wilson, B J ^b   Shadbolt, B ^a   Brook, A S ^a,b   Dorai Raj, A K ^a,b   Khoo, K B K ^b  

^a CANBERRA HOSPITAL   (Australia)

^b Canberra Rheumatology   (Australia)

Author keywords

Ankylosing spondylitis; Infliximab; Spinal ankylosis; Treatment; Tumour necrosis factor

Indexed keywords

HLA B27 ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CLINICAL PRACTICE; CONSENSUS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE REACTION; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS; MALE; MORNING STIFFNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; RADIODIAGNOSIS; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 45749146222     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01599.x     Document Type: Article

References (15)

1. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002 46 : 223 31.
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 359 : 1187 93.
3. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl J Med 2002 346 : 1349 56.
4. Davis JC Jr., van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al. for the Enbrel Ankylosing Spondylitis Study Group. Recombinant tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomised, controlled trial. Arthritis Rheum 2003 48 : 3230 36.
5. Calin A, Dijkman BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004 63 : 1594 600.
6. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al. for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomised, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 52 : 582 91.
7. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans B, Braun J et al. for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicentre, randomised, double-blind, placebo-controlled trial (ATLAS). Arthritis Rheum 2006 54 : 2136 46.
8. Van der Linden SM, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984 27 : 361 8.
9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 21 : 2286 91.
10. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al. A new approach in to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 21 : 2281 5.
11. Jones SD, Steiner A, Garrett SL, Calin A. The bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 1996 35 : 66 71.
12. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 44 : 1876 86.
13. Ware JE, Sherbourne CD. The MOS 36 item short form health survey (SF-36):1. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
14. Stevenson CE. SF-36: Interim Norms for Australian Data. Canberra : Australian Institute of Health and Welfare 1996.
15. Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open label study. Rheumatology 2002 41 : 1280 85.